Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men
Inhaled mosliciguat had a longer t<sub>max</sub> and half-life than oral mosliciguat. Accumulation data suggest formation of a mosliciguat depot in the lungs and continuous transfer to the systemic circulation, with an indication of an increase in accumulation ratio with longer duration of treatment.
Authors
- Tobias Mundry
- Ulf Buetehorn
- Johannes Nagelschmitz (ORCID: https://orcid.org/0000-0002-1039-3173)
- Sylvia Nikkho (ORCID: https://orcid.org/0000-0003-1245-2656)
- Soundos Saleh (ORCID: https://orcid.org/0009-0000-9370-5816)
- Stephan Holzschuh
Institutions
- Bayer (Germany) (DE)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1007/s40262-025-01503-6
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Bayer
- Roivant Sciences